Concepts (210)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 6 | 2026 | 702 | 2.190 |
Why?
|
| Machine Learning | 3 | 2026 | 60 | 1.550 |
Why?
|
| Patient Readmission | 4 | 2021 | 161 | 1.290 |
Why?
|
| Psychotic Disorders | 1 | 2026 | 52 | 0.890 |
Why?
|
| Intensive Care Units | 4 | 2021 | 102 | 0.680 |
Why?
|
| Aftercare | 1 | 2021 | 46 | 0.670 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 410 | 0.640 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 94 | 0.610 |
Why?
|
| Patient Discharge | 1 | 2021 | 152 | 0.600 |
Why?
|
| Critical Care Outcomes | 1 | 2018 | 1 | 0.580 |
Why?
|
| Critical Illness | 1 | 2018 | 53 | 0.540 |
Why?
|
| Natural Language Processing | 1 | 2018 | 60 | 0.530 |
Why?
|
| Hospitalization | 3 | 2021 | 816 | 0.530 |
Why?
|
| Retrospective Studies | 8 | 2026 | 2463 | 0.510 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 515 | 0.460 |
Why?
|
| Medical Informatics Applications | 1 | 2015 | 5 | 0.440 |
Why?
|
| Data Mining | 1 | 2015 | 18 | 0.440 |
Why?
|
| Support Vector Machine | 1 | 2014 | 2 | 0.420 |
Why?
|
| Classification | 1 | 2014 | 2 | 0.420 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 17 | 0.410 |
Why?
|
| Humans | 18 | 2026 | 16832 | 0.370 |
Why?
|
| Male | 16 | 2026 | 9556 | 0.350 |
Why?
|
| Risk Assessment | 3 | 2021 | 1047 | 0.330 |
Why?
|
| Female | 12 | 2026 | 12193 | 0.310 |
Why?
|
| Aged | 6 | 2021 | 5901 | 0.280 |
Why?
|
| California | 3 | 2026 | 2244 | 0.270 |
Why?
|
| Middle Aged | 6 | 2021 | 7515 | 0.250 |
Why?
|
| Adult | 5 | 2026 | 7255 | 0.240 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 1233 | 0.210 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 16 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 24 | 0.210 |
Why?
|
| Young Adult | 3 | 2026 | 2456 | 0.180 |
Why?
|
| Fractures, Multiple | 1 | 2021 | 1 | 0.180 |
Why?
|
| Rib Fractures | 1 | 2021 | 2 | 0.180 |
Why?
|
| Spinal Fractures | 1 | 2021 | 12 | 0.180 |
Why?
|
| Frailty | 1 | 2021 | 13 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 41 | 0.170 |
Why?
|
| Triage | 1 | 2021 | 24 | 0.170 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 97 | 0.170 |
Why?
|
| Doxorubicin | 4 | 1990 | 4 | 0.160 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 6 | 0.160 |
Why?
|
| Mortality | 1 | 2021 | 116 | 0.160 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 325 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2021 | 211 | 0.160 |
Why?
|
| Personnel Management | 1 | 2020 | 3 | 0.160 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 8 | 0.160 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 15 | 0.160 |
Why?
|
| Workplace | 1 | 2020 | 34 | 0.150 |
Why?
|
| Health Services Research | 1 | 2020 | 180 | 0.150 |
Why?
|
| Adolescent | 2 | 2026 | 3464 | 0.150 |
Why?
|
| Nurses | 2 | 2020 | 32 | 0.150 |
Why?
|
| Sex Factors | 1 | 2020 | 560 | 0.140 |
Why?
|
| Health Status | 1 | 2020 | 256 | 0.140 |
Why?
|
| Physicians | 1 | 2020 | 114 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2018 | 16 | 0.140 |
Why?
|
| Age Factors | 1 | 2020 | 814 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 29 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 43 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 393 | 0.130 |
Why?
|
| Interferon-gamma | 3 | 1988 | 7 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 346 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 520 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2018 | 164 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 222 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2016 | 21 | 0.120 |
Why?
|
| Medical Audit | 1 | 2016 | 31 | 0.120 |
Why?
|
| Risk Factors | 2 | 2020 | 3108 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 1887 | 0.120 |
Why?
|
| Acute Disease | 1 | 2016 | 144 | 0.110 |
Why?
|
| Iron | 1 | 2015 | 14 | 0.110 |
Why?
|
| Anemia | 1 | 2015 | 34 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2015 | 57 | 0.110 |
Why?
|
| Animals | 14 | 2010 | 237 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 169 | 0.110 |
Why?
|
| Communication | 1 | 2016 | 183 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 7 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2016 | 205 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 261 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 144 | 0.100 |
Why?
|
| Jaundice, Neonatal | 1 | 2014 | 17 | 0.100 |
Why?
|
| Phototherapy | 1 | 2014 | 23 | 0.100 |
Why?
|
| Electrolytes | 2 | 1984 | 3 | 0.100 |
Why?
|
| Myocardium | 2 | 1984 | 6 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 37 | 0.100 |
Why?
|
| United States | 5 | 2021 | 3858 | 0.100 |
Why?
|
| Telemedicine | 1 | 2016 | 190 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2014 | 828 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 913 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2018 | 294 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 3 | 0.080 |
Why?
|
| Biological Products | 1 | 2010 | 6 | 0.080 |
Why?
|
| Hospitals | 2 | 2021 | 69 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 114 | 0.080 |
Why?
|
| Mice | 8 | 1989 | 59 | 0.080 |
Why?
|
| Biotechnology | 2 | 2010 | 2 | 0.070 |
Why?
|
| Drug Design | 2 | 2010 | 2 | 0.070 |
Why?
|
| Collagen | 2 | 1990 | 8 | 0.070 |
Why?
|
| Pulmonary Fibrosis | 1 | 1986 | 10 | 0.060 |
Why?
|
| Viruses | 1 | 1985 | 1 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 311 | 0.050 |
Why?
|
| Verapamil | 1 | 1984 | 1 | 0.050 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1984 | 3 | 0.050 |
Why?
|
| Protein Engineering | 1 | 2003 | 1 | 0.050 |
Why?
|
| Drug Approval | 1 | 2003 | 11 | 0.050 |
Why?
|
| Drug Industry | 1 | 2003 | 4 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 33 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2021 | 9 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2021 | 6 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 88 | 0.040 |
Why?
|
| Interferon Type I | 3 | 1985 | 4 | 0.040 |
Why?
|
| Geographic Mapping | 1 | 2020 | 3 | 0.040 |
Why?
|
| Technology | 1 | 2020 | 5 | 0.040 |
Why?
|
| Patient Care | 1 | 2020 | 31 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 1 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 12 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 39 | 0.030 |
Why?
|
| Mastectomy | 1 | 2018 | 34 | 0.030 |
Why?
|
| Breast | 1 | 2018 | 66 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 56 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 322 | 0.030 |
Why?
|
| DNA, Recombinant | 3 | 1985 | 3 | 0.030 |
Why?
|
| Diagnosis | 1 | 2016 | 3 | 0.030 |
Why?
|
| Vascular Grafting | 1 | 2015 | 1 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 6 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2396 | 0.030 |
Why?
|
| Erythrocyte Transfusion | 1 | 2015 | 9 | 0.030 |
Why?
|
| Bacteremia | 1 | 2015 | 11 | 0.030 |
Why?
|
| Plasminogen Activators | 2 | 1984 | 2 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 169 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2016 | 155 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 171 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2016 | 249 | 0.030 |
Why?
|
| Magnesium | 2 | 1984 | 6 | 0.030 |
Why?
|
| Sodium | 2 | 1984 | 14 | 0.030 |
Why?
|
| Potassium | 2 | 1984 | 14 | 0.030 |
Why?
|
| Calcium | 2 | 1984 | 27 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 188 | 0.020 |
Why?
|
| Medicaid | 1 | 2014 | 189 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 989 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1990 | 3 | 0.020 |
Why?
|
| Wound Healing | 1 | 1990 | 3 | 0.020 |
Why?
|
| Biopharmaceutics | 1 | 2010 | 1 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 23 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 110 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1989 | 1 | 0.020 |
Why?
|
| Oxygen | 1 | 1989 | 14 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1989 | 24 | 0.020 |
Why?
|
| Yellow Fever | 1 | 1988 | 2 | 0.020 |
Why?
|
| Viremia | 1 | 1988 | 9 | 0.020 |
Why?
|
| Half-Life | 3 | 1985 | 5 | 0.020 |
Why?
|
| Kinetics | 3 | 1984 | 12 | 0.020 |
Why?
|
| Hydroxyproline | 1 | 1986 | 1 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1988 | 10 | 0.010 |
Why?
|
| Liver | 1 | 1985 | 31 | 0.010 |
Why?
|
| Encephalomyocarditis virus | 1 | 1985 | 1 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1985 | 4 | 0.010 |
Why?
|
| Primates | 1 | 1984 | 1 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1984 | 2 | 0.010 |
Why?
|
| Rats | 3 | 1990 | 33 | 0.010 |
Why?
|
| Heart | 1 | 1984 | 8 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 51 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 3 | 0.010 |
Why?
|
| Diet | 1 | 1984 | 349 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1981 | 1 | 0.010 |
Why?
|
| Biotransformation | 1 | 1981 | 3 | 0.010 |
Why?
|
| Saimiri | 2 | 1988 | 2 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1989 | 4 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1984 | 6 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1990 | 1 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1990 | 5 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1990 | 7 | 0.010 |
Why?
|
| Body Weight | 1 | 1990 | 197 | 0.000 |
Why?
|
| Free Radicals | 1 | 1989 | 1 | 0.000 |
Why?
|
| Glutathione | 1 | 1989 | 1 | 0.000 |
Why?
|
| Lipid Peroxides | 1 | 1989 | 1 | 0.000 |
Why?
|
| Maleates | 1 | 1989 | 1 | 0.000 |
Why?
|
| Neoplasm Transplantation | 1 | 1989 | 1 | 0.000 |
Why?
|
| Mice, Nude | 1 | 1989 | 2 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1989 | 2 | 0.000 |
Why?
|
| Acetylcysteine | 1 | 1989 | 2 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1988 | 3 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 32 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1988 | 18 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1988 | 17 | 0.000 |
Why?
|
| Antipyrine | 1 | 1985 | 1 | 0.000 |
Why?
|
| Benzoflavones | 1 | 1985 | 1 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 1 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1985 | 1 | 0.000 |
Why?
|
| Mice, Inbred ICR | 1 | 1985 | 2 | 0.000 |
Why?
|
| Carbon Radioisotopes | 1 | 1985 | 2 | 0.000 |
Why?
|
| Cimetidine | 1 | 1985 | 2 | 0.000 |
Why?
|
| Breath Tests | 1 | 1985 | 5 | 0.000 |
Why?
|
| Pan troglodytes | 1 | 1984 | 1 | 0.000 |
Why?
|
| Papio | 1 | 1984 | 2 | 0.000 |
Why?
|
| Species Specificity | 1 | 1984 | 5 | 0.000 |
Why?
|
| Macaca | 1 | 1984 | 5 | 0.000 |
Why?
|
| Jugular Veins | 1 | 1984 | 1 | 0.000 |
Why?
|
| Rabbits | 1 | 1984 | 5 | 0.000 |
Why?
|
| Thrombosis | 1 | 1984 | 16 | 0.000 |
Why?
|
| Fibrinolytic Agents | 1 | 1984 | 45 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1983 | 4 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1983 | 10 | 0.000 |
Why?
|
| Nephrectomy | 1 | 1983 | 6 | 0.000 |
Why?
|
| Hexobarbital | 1 | 1983 | 1 | 0.000 |
Why?
|
| Microsomes, Liver | 1 | 1983 | 1 | 0.000 |
Why?
|
| Acetaminophen | 1 | 1983 | 4 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1983 | 17 | 0.000 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1983 | 6 | 0.000 |
Why?
|
| Sleep | 1 | 1983 | 54 | 0.000 |
Why?
|
Concepts
(210)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->